FDA Commissioner Marty Makary Resigns Amid Pressure and Agency Turmoil

1-Minute Brief

Makary's departure highlights ongoing tensions over FDA policies and leadership amid political and industry pressures.

Key Facts

• FDA Commissioner Marty Makary has resigned after a period of public speculation and pressure.
• Makary's resignation follows reported clashes with the Trump administration and controversy over issues including flavored vapes and abortion drugs.
• Pharmaceutical companies, anti-abortion groups, and vaping lobbyists were among those expressing dissatisfaction with Makary's leadership.
• Makary's tenure as FDA commissioner lasted 13 months.
• Dr. Diamantas has been named as the acting FDA commissioner following Makary's resignation.

What Happened

Dr. Marty Makary resigned as head of the US Food and Drug Administration after facing pressure from political, industry, and advocacy groups. Dr. Diamantas has been appointed as acting commissioner.

Why It Matters

The resignation underscores challenges facing the FDA as it navigates contentious policy debates and external pressures. Leadership changes at the agency may affect regulatory decisions and public health policy.

What's Next

Observers are watching for potential shifts in FDA policy and further appointments to fill key vacancies. The agency's direction under new leadership remains to be seen.